Obesity, the most prevalent nutritional disorder in the world, is characterized by an increase in fat mass. The increasing prevalence and the associated metabolic comorbidities of obesity in af¯uent societies, coupled with the recalcitrance to successful treatment, have increasingly focused the need for newer treatment approaches based on a better understanding of the pathophysiology of obesity. When food intake chronically exceeds energy expenditure, most of the surfeit of energy is stored in the form of triacylglycerols in adipose tissue. Expansion of adipose tissue mass can be accomplished by an increase in the cell size, cell number or both. Mild obesity (WHO class 1 and class 2 obesity) is typically associated with increased adipocyte size (hypertrophic obesity), whereas more severe forms of obesity in animals and humans (class 3 obesity) are accompanied by both an increase in fat cell size and number (hyperplastic obesity). Childhood obesity often involves adipocyte hyperplasia and appears to be more refractory to treatment. Weight loss is associated with a decrease in fat cell size through mobilization of triacylglycerols or lipolysis. Whether there is also a reduction in the cell number observed with weight loss, and whether or not there is reversion of mature fat cells to the immature phenotypes, is unclear.
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The past three decades of adipose cell biology research have witnessed three important eras of discovery. The ®rst era was marked by the discovery and identi®cation of preadipocytes, and the elaboration of propagating cell cultures in the seventies. Studies on 3T3 fatty ®broblasts and preadipocytes from rodents and humans have enabled us to increasingly recognize the pivotal role of preadipocyte proliferation and differentiation in contributing to the formation of new mature fat cells. The second era coincided with the advances in cellular and molecular biology, which began in the late seventies and mid-eighties. We witnessed an explosion of data af®rming that adipose tissue is no longer viewed as a passive reservoir for energy storage, but rather one of the most metabolically active organs in the body. Adipose tissue is a secretory organ that releases an ever increasing number of bioactive mediators that act via endocrine, paracrine, autocrine andaor juxatacrine modes of action in¯uencing lipid and carbohydrate metabolism, and overall energy homeostasis. A signi®cant discovery that fueled the excitement in obesity research is that of leptin, a fat-cell speci®c hormone that functions as a signaling molecule on the brain to complete the negative feedback loop of the lipostatic theory of weight control. The third era of adipose cell biology research, focused on the transcriptional control of fat cell differentiation and gene expression, has greatly facilitated our understanding of the fundamental processes involved in fat cell development and growth, and brings hope for future discoveries that may yield therapeutic bene®ts.
Several transcription factors are signi®cantly increased during preadipocyte differentiation and all are involved in regulating adipogenesis. The ®rst, peroxisome proliferator activated receptor-g (PPARg), is a member of the nuclear hormone receptor superfamily that heterodimerizes with retinoid X receptor, another nuclear hormone receptor. PPARg-2 is the predominant isoform found in fat cells. The second transcription factor belongs to the basic-leucine zipper family of CAATaenhancing binding proteins (CaEBPs), for which there are six isoforms. CaEBPb and CaEBPd are expressed early and may function as early transcription activators, augmenting CaEBPa and PPARg expression in the sequence of events leading to adipocyte differentiation. Targeted genetic disruption of CaEBPa and PPARg expression can result in dramatic reduction in the lipid content and mass of adipose tissue. A Pro114Gln mutation in PPARg accelerates adipocyte differentiation and has been reported in a small number of patients with obesity and insulin resistance, whereas Pro12Ala polymorphism decreases receptor activity and is linked to lower body mass index. The cooperative and possibly synergistic interactions between CaEBPa and PPARg have been described in in vitro and in vivo studies, suggesting a relevant physiologic role for these transcription factors during adipocyte differentiation. The third transcription factor, adipocyte determination and differentiation factor-1 (ADD1), also known as steroid binding protein-1c (SREBP1c), is a member of the basic helix ± loop ± helix family of transcription factors. ADD1aSREBP1c appears to promote adipogenesis by augmenting the transcriptional activity of PPARg, as well as inducing differentiation-dependent lipogenic enzymes, such as fatty acid synthase and lipoprotein lipase.
Meanwhile, exciting research on the genetics of obesity has taught us that, unlike animal models of obesity, where a number of monogenic mutations have been elegantly elucidated, including the discovery of leptin and leptin receptor de®ciencies in obese rodents, only about 30 ± 40% of the variance in body fat mass in humans can be ascribed to genetic factors.
While the precise cellular signals regulating adipogenesis are beginning to become unraveled, many more unanswered questions remain. The ®rst session of this symposium reviewed and addressed different aspects of the cellular and molecular control of adipogenesis.
Intensive investigations to date have focused on the elucidation of endocrine, paracrine, autocrine and juxtacrine factors leading to expansion of adipose tissue mass. Little, however, is known on cellular mechanisms responsible for the contraction of adipose tissue mass that occurs during negative energy balance resulting in weight loss. In the ®rst paper, Alexander Sorisky introduced the emerging concept of a potential role for apoptosis in contraction of adipose tissue mass. Apoptosis, or programmed cell death, ®rst described in human fat tissue explants, has been con®rmed in cell culture studies using 3T3, rodent and human preadipocytes. The cytokine, tumor necrosis factor-a (TNFa), which is known to induce apoptosis in a variety of cell types, also induces apoptosis in preadipocytes and this effect appears to be depot-speci®c.
Data from Sorisky's laboratory demonstrated that the susceptibility of fat cells to apoptosis induction is differentiation-dependent, with preadipocytes acquiring progressive resistance to apoptosis as they mature. The expression of two anti-apoptotic proteins, bcl-2 and NAIP, a new member of a family of mammalian inhibitors of apoptosis (IAP), was found to be signi®cantly increased with differentiating 3T3 fatty ®broblasts and rodent preadipocytes. Sorisky also discussed the signaling pathways involved in apoptosis and cell survival, and how the two pathways might be coordinately regulated in fat cells. Further studies will ascertain whether or not mature adipocytes resist or undergo apoptosis, and the potential role of apoptosis in affecting adipose tissue cellularity and mass. Hence, negative energy balance or weight loss can result in a reduction in adipocyte size by depletion of intracellular triacylglycerols content through hormone-stimulated lipolysis, reversion to immature phenotype, and possibly by decreased cell number through apoptosis.
The next two papers dealt with transcriptional control of adipogenesis. By selectively expressing in adipose tissue a dominant negative protein that heterodimerized with and inactivated members of the CaEBP and JUN family of ZIP transcription factors, Marc Reitman and colleagues created a transgenic mouse model, which has virtually no visible white fat. These A-ZIPaF-1 transgenic mice develop hyperglycemia and compensatory hyperinsulinemia and display marked insulin resistance, hypertriglyceridemia, elevated plasma levels of free fatty acids, and hepatic steatosis. The white adipose tissue mass of these mice was reduced by over 95% at birth, yet brown adipose tissue was present and appeared normal quantitatively and morphologically. The A-ZIPaF-1 mice without fat adapt to starvation by rapidly developing torpor, a hibernation-like state, to minimize energy expenditure. Transplantation of white adipose tissue progressively reversed the metabolic and pathophysiologic abnormalities in the A-ZIPaF-1 mice, linking a lack of adipose tissue to the development of insulin resistance, comparable to some forms of lipoatrophic diabetes in humans. Leptin, in contrast to the aP2-SREBP-1c transgenic mouse, failed to restore the diabetes in these transgenic mice, suggesting that leptin de®ciency was not the cause but might contribute to the insulin resistance present in this mouse model. An exciting application of this novel animal model of lipoatrophic diabetes is the elucidation of the pathophysiology of adipose tissue homeostasis through reconstitution of fat tissue by transplantation of different fat-tissue-speci®c knockouts into the AZIPaF-1 mice.
Bruce Spiegelman reviewed the transcriptional control of differentiation in white and brown adipocytes. Emerging and compelling data, mainly from his and other laboratories, suggest that both CaEBPa and PPARg-2 interact synergistically and actively participate in fat cell differentiation. For example, transgenic animals with selective knockouts for CaEBPa, CaEBPb and CaEBPd combination, and PPARg, have greatly reduced body fat. Ligand activation of PPARg also stimulates adipogenesis in vitro and in vivo. While CaEBPb and CaEBPd induce the expression of PPARg, activation of PPARg can also turn on CaEBPa expression. CaEBPa appears to be required to maintain PPARg expression as well as regulating insulin-dependent glucose transport. CaEBPa and PPARg are also involved in the differentiation of brown adipocytes. Brown adipocytes differ from white adipocytes by the presence of abundant mitochondria and the mitochondrial uncoupling protein (UCP-1), which is involved in respiration and thermogenesis. Spiegelman and colleagues recently identi®ed a PPARg-interacting protein, PGC-1, a co-activator which is selectively expressed in brown but not white adipocytes. PGC-1 is cold inducible and may play a role in adaptive thermogenesis. Ectopic expression of PGC-1 in white fat and muscle cells induces expression of UCPs, increased respiration and mitochondrial biogenesis, raising the tantalizing possibility that PGC-1 might be responsible for the commitment of fat cell precursors to become brown adipocytes. PGC-1 may induce mitochondrial biogenesis by augmenting the activity of NRF-1 and NRF-2, both of which bind to and regulate the promoters of several genes encoding mitochondrial proteins. Spiegelman speculated that PGC-1 might play a role in determining the switch between white and brown adipocytes, and increasing PGC-1 activity might become a potential mechanism for energy dissipation and therapeutic target for weight loss. Further studies on the expression in white fat and targeted gene disruption of PGC-1, and other yet to be discovered transcriptional activators and co-activators, will help clarify many unanswered questions on the transcriptional control of adipogenesis.
The next paper by Vicent Gigue Áre highlighted the potential role of another class of orphan nuclear receptors that might play a role in fat metabolism. The estrogen-related receptors (ERRs) display significant homology to the estrogen receptors (ERs), yet they do not bind estrogen and its derivatives in vitro nor respond to them in co-transfection assays. The crystal structure reveals that the amino acid residues critical for the recognition of estradiol are conserved between members of the estrogen receptor and ERR families, suggesting that ER and ERR ligands are structurally similar. The ERR subfamily of receptors comprises 3 closely related members, ERRa, ERRb, and ERRl. ERRa knockout mice revealed intrauterine growth retardation and abnormal adult body composition; they otherwise developed normally with normal reproductive function. Since ERRa is highly expressed in tissues that demonstrate a capacity for fatty acid oxidation or activation, and that it exerts transcriptional control of the expression of mediumchain acyl CoA dehydrogenase in vitro, a role for ERRa in regulating energy metabolism in vivo could be envisioned. The ®ndings that ERRa null mice have hypertrophied fat cells and abnormal triacylglycerol synthesis in the gut and liver are in keeping with such a potential role for ERRa in fat and energy metabolism. It follows from Dr Gigue Áre's talk that an everincreasing list of known and undiscovered orphan nuclear receptors, such as ERRa, and their ligands, may constitute excellent targets for control of adipose tissue development and growth.
The ®nal paper of the session, presented by HeiSook Sul, addressed the role of a novel protein secreted by preadipocytes, preadipocyte factor-1 (pref-1), which exerts negative control of adipogenesis. Under normal cell culture conditions, 3T3-L1 ®broblasts and preadipocytes can be induced to undergo maturation by enrichment of the culture medium with hormones and substrates. After several rounds of cell division to reach monolayer con¯uence, preadipocytes exit from the cell cycle with growth arrest. Differentiation requires not only cell cycling arrest and expression of speci®c transcription factors, but also a proper extracellular matrix environment to transduce the external signals to the nucleus via a cascade of intracellular signaling steps. The classical hormonal cocktail used for differentiation induction includes glucocorticoids and insulin, but the precise cellular mechanisms for differentiation induction are not well understood. Sul and her colleagues have now adduced evidence that dexamethasone, a synthetic glucocortoticoid, is a potent inhibitor of pref-1 expression. Pref-1, a 50 kDa membrane-associated protein of 385 amino acids with six tandem EGF-repeats in the extracellular domain, was originally cloned by differential screening by Sul and shown to inhibit differentiation of 3T3-L1 cells. Pref-1 is highly expressed in preadipocytes but its expression is down-regulated with maturation and is barely detected in mature fat cells. Since dexamethasone-suppression of pref-1 and transfected antisense pref-1 expression augment adipogenesis, pref-1 appears to function either as an inhibitor of adipose cell differentiation, or to maintain preadipocytes in the undifferentiated state by yet unde®ned mechanisms. Sul also provided information that the juxtacrine or paracrine mode of action of pref-1 is largely dependent on its isoforms generated via alternative splicing. What is also intriguing is the preliminary data presented to suggest that constitutive pref-1 expression may be an early event that precedes an increase in CaEBPa and PPARg expression. Attenuation of the pref-1 signaling may be a prerequisite for inducing adipose cell differentiation. Studies on the cell ± cell communication and cell ± matrix interaction between pref-1 and various hormonal and growth factors, and the elucidation of pref-1 receptors, will provide further insights into the complex extracellular and intracellular pathways controlling adipogenesis.
The speakers in this session have elegantly updated the readers with some of the key advances in adipose cell biology knowledge. Studies to date have enabled us to construct a working model of the major processes involved in the positive and negative control of preadipocyte differentiation and proliferation. Another important bene®t of adipose cell biology research is the insight into the role of fat in the development of insulin resistance and the metabolic comorbidities that compromise the health of the obese state. It is likely that many more endocrine, novel paracrine, autocrine and juxtacrine fat cell-derived growth factors await discovery to complete our understanding of the complex and dynamic interactions occurring in adipose tissue that eventually determine body fat mass and cellularity. Future work will continue to unravel the fundamental processes involved in the transcriptional control and the cascade of intracellular signaling pathways regulating adipogenesis. The next steps will probably focus on the identi®ca-tion of the mesenchymal stem cells and early precursors that are destined to become adipocytes. Whether white and brown adipocytes are derived from the same precursors and whether these cells can be transformed into one another will be of great interest. The search for the magic bullet to treat and prevent obesity will continue to fuel excitement in adipose cell biology research in the hope that future discoveries will translate into therapeutic bene®ts.
